Epoprostenol use in a National Pulmonary Hypertension Centre from 1997 to 2007

Thorax

Volumn 64, Issue 7, 2009, Pages 642-

  Church, A C ^a,b   Sanabria, D ^a   Peacock, A ^a   Johnson, M ^a  

^a Scottish Pulmonary Vascular Unit   (United Kingdom)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PROSTACYCLIN; PROSTANOID;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EUROPE; HUMAN; LETTER; MORTALITY; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNITED KINGDOM; UNITED STATES;

EID: 67650245607     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2008.110643     Document Type: Letter

References (5)

1. National Institute for Health and Clinical Excellence (NICE). Appraisal document. London: NICE, 2008.
2. National Pulmonary Hypertension Centres of the UK and Ireland. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Thorax 2008;63(Suppl 2):ii1-41.
3. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):35-62S.
4. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.